BrightSpring's +80% EPS Is a Specialty-Pharmacy Beat, Not a Home-Care Margin Story

Pharmacy Solutions revenue of $3,732 million grew 26% and its segment EBITDA rose 43%, putting $61 million of the $68 million adjusted EBITDA increase into the pharmacy book. Provider Services, the segment that actually delivers home health and hospice care, grew revenue 31% and EBITDA 30% — a rounding error next to the pharmacy.

Provider Services is where the profit sits and where the surprise is not. It produced 11.4% of revenue but 28.1% of segment EBITDA, at a 16.4% margin that slipped 20 basis points even as revenue grew 31%. Three things explain it: revenue bought rather than earned, a mix shift toward lower-margin home health, and labor costs that are not getting cheaper.

Rate is the layer that genuinely works, and it lands on January 1, 2027. CMS's CY2027 home health rule hands agencies a 2.4% aggregate increase with no permanent clawback for the first time in three years, and the FY2027 hospice update adds 2.3% while lifting the aggregate cap to $36,175.

Industry volume is growing — Humana's CenterWell home solutions logged 83,150 episodic admissions in the second quarter, up 5.6% — but the labor market keeps agency rates for clinical staff firm instead of easing them. Cross Country Healthcare's home-based staffing division grew 16% while the rest of the staffing market shrank 17.8%, which is precisely why a31% revenue increase at BrightSpring's provider segment produced no margin expansion.

The peer set says the same thing in a different language. Chemed's VITAS hospice unit runs a 20.2% adjusted EBITDA margin, Addus HomeCare converts 11.6% of revenue into EBITDA on Medicaid-funded personal care, and The Pennant Group grows home health and hospice revenue 43% on a 14.1% gross margin. Only the specialty pharmacy book carries a 5.4% margin, and it is 89% of BrightSpring's revenue.

UnitedHealth Group's retreat from home health is what put assets on the market. Optum sold Amedisys and LHC Group branches to BrightSpring for $239 million in February 2026 while Optum Health revenue fell 10%, putting the same asset class on the market at roughly 0.8x revenue against about 1.0x for the platform Kinderhook paid to take Enhabit private.

At $66.89, the stock trades on roughly 18x its own guided adjusted EBITDA, with net leverage of 1.79x and trailing free cash flow of about $492 million. Guidance implies about a 7.7% incremental margin on $3.1 billion of new revenue — above today's blended 5.4%, which is the arithmetic of a pharmacy-led mix.

Six weeks of November results decides two of the three legs of the thesis. Provider segment EBITDA margin is the only number that can re-rate the stock, and it prints with the fourth quarter in late February.

Over one to three years the care business is a call option on artificial-intelligence productivity and on the hospice cap, not the source of earnings growth. Management put AI returns in 2027, as documentation, medication review and hiring automation finish rolling out, and the Medicare cap that suppressed hospice margins is already clearing.

The premise needs correcting: volume works, rate works from 2027, and labor does not work yet. The right way to own this is as a pharmacy compounder with a care option attached, not as a home-care margin story. The upside case is that provider margin moves from 16.4% toward 18% on automation and integration, worth roughly $30 million of EBITDA on about $1.9 billion of provider revenue — meaningful, but a rounding error against $855 million of guided company EBITDA.

What would change the read: provider segment EBITDA margin above 17% with home health revenue still compounding at a double-digit rate, which would mean the care business is earning its multiple rather than borrowing it from the pharmacy. What would confirm the caution: another quarter in which consolidated adjusted EBITDA beats, provider margin stays at 16.4%, and the stock still trades near 18x guided EBITDA.